Hemophilia

Clinical Trial of New Recombinant Therapy Initiated

Published in Blood Weekly, December 7th, 2000

Baxter Healthcare Corporation announced that its Hyland Immuno business has initiated a Phase III clinical trial of its new recombinant Factor VIII therapy for the treatment of hemophilia A.

This new recombinant Factor VIII excludes any added proteins or raw materials derived from human or animal sources in the manufacture, purification, and formulation of the final product. The product is, thereby, designed to virtually eliminate the theoretical risk of transmission of infectious agents potentially associated with products which contain human or animal-derived additives. Factor VIII, or antihemophilic factor, is the protein in human blood that is critical for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-12-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry